In connection with practice and science - MEB annual report 2017
The 2017 annual report of the Medicines Evaluation Board (MEB) has been published. Use this opportunity to look back on what happened in this past and, in many respects, exciting year. Find out which shadows were cast in 2017 on important developments to come. Read about how the organisation's core values - scientific, in connection and watchful - give direction to how the MEB fulfils its tasks and responsibilities and have a look at the overview of the figures of 2017.
Some of the highlights:
Departure of Prof. Bert Leufkens and appointment of new chairman Prof. Ton de Boer
After having worked for the MEB for 10 years, chairman Prof. Bert Leufkens stepped down in the summer of 2017. In an interview in the annual report, the new chairman Prof. Ton de Boer offers some food for thought. For example on streamlining procedures in the development, authorisation and compensation of medicines. He also talks about including the beneficial effects of a medicine in the patient information leaflet. According to De Boer, their inclusion would help promote better use of medicines.
The impact of Brexit and the relocation of the EMA on the MEB
It was a festive occasion when it was announced at the end of 2017 that the European Medicines Agency would be coming to Amsterdam in 2019. In an interview MEB Director Hugo Hurts looks back on this exciting decision and on the MEB's contribution to the Dutch bid for the EMA. He also discussses the consequences of Brexit for the MEB. In a video he also looks ahead: what will it mean for the MEB that the EMA is coming to Amsterdam?
Important developments in European legislation
The work in Brussels on two important European regulations for veterinary medicines neared its completion in 2017. Read about the impact this legislation will have on the authorisation of veterinary medicinal products in the chapter about the MEB's Veterinary Medicinal Products Unit.
Digital risk information for healthcare providers
Important risk information about medicines is sent to doctors and pharmacists via letters (also known as DHPCs). But are they still sufficient in this day and age when it comes to quickly and effectively communicating vital new information? The MEB annual report discusses a pilot project by the MEB, the Health and Youth Care Inspectorate (IGJ) and the Netherlands Pharmacovigilance Centre Lareb to send risk information digitally to healthcare providers in a quick and efficient manner. MEB programme manager Nanneke Hendricks looks ahead in a video at her ideal future scenario for the distribution of new risk information on medicines.
Interchangeability of generic medicines
Three MEB researchers discuss their research into the interchangeability of generic medicines (i.e. 'switching'). In order to increase the confidence in generic medicines, the MEB published a leaflet about them in 2017. This leaflet was developed in cooperation with 10 patients’ and consumers’ organisations, including the Dutch Consumers’ Association and the Dutch Patients’ Federation. More than 75,000 printed copies were requested in 2017 by doctors and pharmacists.
The Medicine shortages and defects notification centre: one year in
The Medicine shortages and defects notification centre was launched on 1 January 2017. Companies made nearly 400 notifications of delivery problems with regard to medicines. Which parties work together at the notification centre and what takes place behind the scenes? You can read about this in the MEB annual report 2017.